Status:
COMPLETED
Alterations in Cognitive Function and Cerebral Blood Flow After Conversion From Calcineurin Inhibitors (CNIs) to Everolimus
Lead Sponsor:
University of Kansas Medical Center
Collaborating Sponsors:
Novartis Pharmaceuticals
Conditions:
End Stage Renal Disease
Eligibility:
All Genders
18-85 years
Brief Summary
The purpose of this study is to learn if changing from Tacrolimus to Everolimus will improve cognitive function by having less effect on brain blood flow.
Eligibility Criteria
Inclusion
- English speaking
- able to sign informed consent
- able to arrange transportation to and from study site
- without acute stroke, concussion or traumatic brain injury
- without acute medical issues at the time of participation
- At least 12 weeks post Kidney transplant surgery
Exclusion
- are claustrophobic or have other contra-indication for magnetic resonance imaging (MRI)
- have hearing or visual impairment
- are unable to read, write, speak or understand English
- have uncontrolled psychosis or seizure disorder or are currently using antipsychotics or anti-epileptics
- taking Envarsus at the time of recruitment
Key Trial Info
Start Date :
February 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2022
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT03413722
Start Date
February 1 2018
End Date
October 1 2022
Last Update
October 22 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Kansas Medical Center
Kansas City, Kansas, United States, 66160